The Current Ratio as of September 2024 (TTM) for Roivant Sciences Ltd. (ROIV) is 27.91

According to Roivant Sciences Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 27.91. This represents a change of 28.64% compared to the average of 21.70 of the last 4 quarters.

Roivant Sciences Ltd. (ROIV) Historical Current Ratio (quarterly & annually)

How has ROIV Current Ratio performed in the past?

The mean historical Current Ratio of Roivant Sciences Ltd. over the last ten years is 13.86. The current 27.91 Current Ratio has changed 20.03% with respect to the historical average. Over the past ten years (40 quarters), ROIV's Current Ratio was at its highest in in the June 2024 quarter at 27.91. The Current Ratio was at its lowest in in the June 2020 quarter at 0.

Roivant Sciences Ltd. (ROIV) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Roivant Sciences Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Roivant Sciences Ltd. (ROIV) Average Current Ratio

How has ROIV Current Ratio performed in the past?

The current Current Ratio of Roivant Sciences Ltd. (ROIV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Roivant Sciences Ltd. (ROIV) Current Ratio vs. Peers

How is ROIV’s Current Ratio compared to its peers?

Roivant Sciences Ltd.’s Current Ratio is less than Krystal Biotech, Inc. (0), greater than Prometheus Biosciences, Inc. (9.50), less than Akero Therapeutics, Inc. (37.56), greater than Apellis Pharmaceuticals, Inc. (24.89), greater than Day One Biopharmaceuticals, Inc. (5.08), greater than Phathom Pharmaceuticals, Inc. (4.09), greater than Blueprint Medicines Corporation (6.48), greater than Lyra Therapeutics, Inc. (3.71), greater than Cullinan Oncology, Inc. (3.60), less than Ascendis Pharma A/S (28.87), greater than BeiGene, Ltd. (0.74), greater than Pliant Therapeutics, Inc. (1.98), greater than Syndax Pharmaceuticals, Inc. (14.47), greater than Revolution Medicines, Inc. (10.50), greater than Viridian Therapeutics, Inc. (15.42), greater than Inozyme Pharma, Inc. (15.82), greater than null (9.84),

Build a custom stock screener for Roivant Sciences Ltd. (ROIV) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Roivant Sciences Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Roivant Sciences Ltd. (ROIV) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Roivant Sciences Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.